Navigation Links
AbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies
Date:9/3/2014

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Sept. 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.

Calico is the Google-backed life sciences company that is led by Arthur D. Levinson Ph.D. (former chairman and CEO of Genentech) and Hal V. Barron, M.D. (former Executive Vice President and Chief Medical Officer of Genentech). The agreement paves the way for Calico to establish a world-class research and development facility in the San Francisco Bay Area.  

Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases:

  • Calico will use its scientific expertise to establish a world-class research and development facility, with a focus on drug discovery and early drug development
  • AbbVie will provide scientific and clinical development support and its commercial expertise to bring new discoveries to market

"This collaboration demonstrates our commitment to exploring new areas of medicine and innovative approaches to drug discovery and development that augments our already robust pipeline," said Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie.  "We are pleased to be working with such outstanding scientists as Art Levinson, Hal Barron and their team.  The potential to help improve patients' lives with new therapies is enormous."

"Our relationship with AbbVie is a pi
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AbbVie Announces Inaugural Week of Possibilities Volunteer Program to Support Six Schools in North Chicago, Ill., and Worcester, Mass.
2. AbbVie and North Chicago Public Schools Announce $350,000 Grant to Advance Math Education
3. AbbVie to Present at Jefferies 2013 Healthcare Conference
4. AbbVie to Present at Credit Suisse 2013 Healthcare Conference
5. AbbVie to Present at Morgan Stanley Global Healthcare Conference
6. Vote to Help Award a $21,000 AbbVie CF Scholarship to Two Inspirational Students with Cystic Fibrosis Pursuing their Goals of Higher Education
7. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
8. StockCall Scrutinizes Pfizer, Merck & Co., Johnson & Johnson, and AbbVie
9. AbbVie to Present at Cowen and Company 33rd Annual Health Care Conference
10. AbbVie Declares Dividend and Announces Share Repurchase Program
11. Seoul Viosys Co., Ltd. Announced Viophoton Technology to Lead the Innovation of Household Appliances and Biomedical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for ... current system received a score of 0 (range -10 to +10) for its impact ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes ...
(Date:7/29/2015)... ... , ... Finding gooey or crusty material in the corner of your eyes ... number of terms in popular use to describe it, ophthalmologists call it “gound” or ... blood cells, skin cells and dust, but until now there has been virtually no ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering ... the Orange County, Texas area from future storm surge flooding, such as occurred in ... potential levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Preventing Storm Surge Flooding in Houston 2
... Safety Nets to Prevent Serious Health Hazards ... Associated with ... U.S. Pharmacopeial (USP),Convention today announced a revised Glycerin monograph ... the United States. The,revision strengthens safety nets to prevent ...
... March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ... Dr. Kevin,Harrington and his research group at ... the results of their work characterizing immune,system ... a Phase I,clinical trial. The paper, entitled ...
... by the Greater Baltimore Committee:, WHO:, Donald ... 140 company owners, executives and researchers from the Baltimore-area,bioscience ... Region Bioscience Awards, WHEN:, Tuesday, March 18, ... 8:45 - 9:30 a.m. / Awards Program, WHERE:, ...
Cached Biology Technology:USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial 2Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... A new assessment of the Arctic,s biodiversity reports a 26 ... Populations of lemmings, caribou and red knot are some ... 34 years, according to the first report from The Arctic ... the Arctic,s ecosystems and wildlife are responding to environmental change. ...
... by Wayne L. Backes, PhD, Professor of Pharmacology and Associate ... School of Medicine, has found that drug metabolism depends not ... also how they interact, and that can be the difference ... or is converted into a toxic or carcinogenic byproduct. The ...
... Angeles, Calif., March 16, 2010Researchers at the Keck School ... have identified a key cellular mechanism that guides embryonic ... to a number of common congenital heart defects. ... the First Heart Field, which includes the left ventricle ...
Cached Biology News:High Arctic species on thin ice 2LSUHSC research increases understanding of drug metabolism 2USC researchers identify key mechanism that guides cells to form heart tissue 2
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Cord blood endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Biology Products: